A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

Are you weening yourself off a compounded version of the drug? Considering switching insurers in order to keep your ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

A new study to be presented at the SLEEP 2025 annual meeting found that sleep medicine professionals favor continuous ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...